Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning

Franco, J. G.; Lisboa, Patrícia Cristina; Lima, Natália S.; Amaral, Taline A.S.; Peixoto-Silva, Nayara; Resende, Ângela Castro; Oliveira, Elaine de; Passos, M. C. F.; Moura, Egberto Gaspar de

doi:10.1016/j.jnutbio.2012.06.019

Cited by 77 publications

(69 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that Resv treatment instituted postweaning (eg, starting at 3-4 weeks) or later (eg, 10 week of age) successfully lowered BP in SHR, 9,10,18 although there was reversion to a hypertensive state on cessation of treatment. 10 These findings suggest that targeting the developmental period with Resv is critical to its long-term effects.…”

Section: Discussionmentioning

confidence: 99%

“…10 These findings suggest that targeting the developmental period with Resv is critical to its long-term effects. Improved NO bioavailability in the vasculature has been proposed to be an important mechanism by which continued Resv supplementation improves cardiovascular function 9,10,18 and prevents pathological vascular remodeling. 19 The finding that l-NAME caused a greater rise in BP, effectively normalizing BPs between SHR and SHR+Resv, suggests that a key mechanism by which Resv causes long-term BP normalization is restoration of NO-mediated signaling.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Perinatal Resveratrol Supplementation to Spontaneously Hypertensive Rat Dams Mitigates the Development of Hypertension in Adult Offspring

et al. 2016

View full text Add to dashboard Cite

ypertension is an important and modifiable risk factor for cardiovascular disease, affecting ≈1 in 4 adults worldwide. 1 In the United States, hypertension is estimated to account for >$46 billion annually in healthcare services, medication, and lost productivity, 2 and these costs are expected to increase substantially over the coming decades. A universal consensus is that prevention, rather than treatment, is a more strategic and cost-effective approach to reducing the burden of cardiovascular disease in coming decades.Essential hypertension, in which known primary causes (eg, renovascular disease, pheochromocytoma, monogenic causes, etc) are not present, makes up 95% of hypertension worldwide.3 Although the pathogenesis of essential hypertension is multifactorial and complex, subclinical changes in vascular function often precede the development of hypertension and circulatory decline. 4 The spontaneously hypertensive rat (SHR) is a model of essential hypertension in which blood pressure (BP) begins to rise after 6 weeks of age, ultimately reaching stable pressures of ≈180 to 200 mm Hg. Recently, Komolova et al reported evidence of altered vascular resistance profiles and renal hemodynamics as early as 3 weeks of age in the SHR, 5 implicating these early functional changes as a cause, rather than a consequence, of hypertension in this model. As such, the developmental period before weaning (ie, See Editorial Commentary, pp 829-830Abstract-This study was undertaken to determine whether perinatal maternal resveratrol (Resv)-a phytoalexin known to confer cardiovascular protection-could prevent the development of hypertension and improve vascular function in adult spontaneously hypertensive rat offspring. Dams were fed either a control or Resv-supplemented diet (4 g/kg diet) from gestational day 0.5 until postnatal day 21. Indwelling catheters were used to assess blood pressure and vascular function in vivo; wire myography was used to assess vascular reactivity ex vivo. Perinatal Resv supplementation in dams had no effect on fetal body weights, albeit continued maternal treatment postnatally resulted in growth restriction in offspring by postnatal day 21; growth restriction was no longer evident after 5 weeks of age. Maternal perinatal Resv supplementation prevented the onset of hypertension in adult offspring (−18 mm Hg; P=0.007), and nitric oxide synthase inhibition (with l-NG-nitroarginine methyl ester) normalized these blood pressure differences, suggesting improved nitric oxide bioavailability underlies the hemodynamic alterations in the Resv-treated offspring. In vivo and ex vivo, vascular responses to methylcholine were not different between treatment groups, but prior treatment with l-NG-nitroarginine methyl ester attenuated the vasodilation in untreated, but not Resv-treated adult offspring, suggesting a shift toward nitric oxide-independent vascular control mechanisms in the treated group. Finally, bioconversion of the inactive precursor big endothelin-1 to active endothelin-1 in isolated mesenteric art...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Perinatal Resveratrol Supplementation to Spontaneously Hypertensive Rat Dams Mitigates the Development of Hypertension in Adult Offspring

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In the purpose to investigate new therapeutic possibilities for weight control in programming models of obesity, our group has been focusing on the effects of resveratrol as a therapeutic supplement to treat metabolic diseases [10,11].…”

Section: Introductionmentioning

confidence: 99%

Resveratrol treatment rescues hyperleptinemia and improves hypothalamic leptin signaling programmed by maternal high-fat diet in rats

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The potential effect of resveratrol in the management of hypertension has been established in pre-clinical setting. In rodent model, resveratrol was effective in preventing obesity and oxidative stress and reducing the risk of hypertension and dyslipidemia in adult rats [10]. Resveratrol subjects) suggested that there was no change in BP after administration of resveratrol (1 g, 1.5 g and 2 g/daily) [14].…”

Section: Rakesh Et Almentioning

confidence: 99%

“…This indicates that the possible use of resveratrol in combination with current anti-hypertensive therapy as an adjuvant therapy would be effective in preventing and treating high BP. Shortterm clinical use of Resveratrol 1 g/daily (500 mg twice daily [BD]) was found to be effective in decreasing BP when compared to placebo after 45 days [10]. Another 4 week clinical study (in 10 subjects) suggested that there was no change in BP after administration of resveratrol (1 g/daily) [11].…”

Section: Introductionmentioning

confidence: 99%

A Randomized Active Controlled Clinical Study to Evaluate Efficacy and Safety of Resveratrol as an Adjuvant Therapy in Patients With Hypertension

Ojha

Pranesh²,

Vyas³

2016

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objectives: No long-term clinical efficacy and safety study of resveratrol as adjuvant therapy along with gold standard therapy has been conducted in patients with essential hypertension. The aim of this study was to investigate the efficacy and safety of resveratrol as an adjuvant therapy in newly diagnosed hypertensive patients. Methods:In this randomized active-controlled study, hypertensive patients (male/female) of 20-65 years aged were randomized (1:1) to receive telmisartan 20 mg or telmisartan 20 mg plus resveratrol 1 g daily for 12 months. Efficacy variables included a change in systolic and diastolic blood pressure (DBP) from baseline and were followed up for every 3 months. Treatment-emergent adverse events were assessed.Results: A total of 60 hypertensive patients were analyzed (telmisartan [n=30] and telmisartan plus resveratrol [n=30]). Resveratrol as an adjuvant with telmisartan significantly reduced in systolic (p<0.001) and DBP (p<0.001) as compared to telmisartan monotherapy. Change in systolic and DBP from baseline was significantly higher in telmisartan plus resveratrol group than telmisartan (p<0.001) at all followed visits. Both the study drugs have similar safety profile and found well tolerable. Conclusions:Resveratrol plus Telmisartan was found to be superior over telmisartan monotherapy in reducing systolic and DBP in newly diagnosed hypertensive patients. Both the study drugs were effective with comparable safety profile. Our study supports the long-term clinical efficacy and safety study of resveratrol along with gold standard therapy in essential hypertension.

show abstract

Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning

Cited by 77 publications

References 54 publications

Perinatal Resveratrol Supplementation to Spontaneously Hypertensive Rat Dams Mitigates the Development of Hypertension in Adult Offspring

Perinatal Resveratrol Supplementation to Spontaneously Hypertensive Rat Dams Mitigates the Development of Hypertension in Adult Offspring

Resveratrol treatment rescues hyperleptinemia and improves hypothalamic leptin signaling programmed by maternal high-fat diet in rats

A Randomized Active Controlled Clinical Study to Evaluate Efficacy and Safety of Resveratrol as an Adjuvant Therapy in Patients With Hypertension

Contact Info

Product

Resources

About